Chifumi Kitanaka
Overview
Explore the profile of Chifumi Kitanaka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mitobe Y, Suzuki S, Nakamura K, Nakagawa-Saito Y, Takenouchi S, Togashi K, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273420
Radiation therapy continues to be the cornerstone treatment for malignant brain tumors, the majority of which express wild-type p53. Therefore, the identification of drugs that promote the ionizing radiation (IR)-induced...
2.
Suzuki S, Kitanaka C, Okada M
Anticancer Res
. 2024 Aug;
44(9):3875-3883.
PMID: 39197897
Background/aim: Glioblastoma is the most aggressive form of brain tumor and has a dismal prognosis; therefore, novel therapeutic approaches based on the mechanisms underlying its aggressive nature are urgently required....
3.
Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Takenouchi S, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612758
The prevention of tumor recurrence by the successful targeting of glioma stem cells endowed with a tumor-initiating capacity is deemed the key to the long-term survival of glioblastoma patients. Glioma...
4.
Togashi K, Suzuki S, Mitobe Y, Nakagawa-Saito Y, Sugai A, Takenouchi S, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201546
Uveal melanoma (UM) is among the most common primary intraocular neoplasms in adults, with limited therapeutic options for advanced/metastatic disease. Since UM is characterized by infrequent p53 mutation coupled with...
5.
Mitobe Y, Suzuki S, Nakagawa-Saito Y, Togashi K, Sugai A, Sonoda Y, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686602
The development of MDM4 inhibitors as an approach to reactivating p53 in human cancer is attracting increasing attention; however, whether they affect the function of MDM2 and how they interact...
6.
Mitobe Y, Suzuki S, Nakagawa-Saito Y, Togashi K, Sugai A, Sonoda Y, et al.
Biomedicines
. 2023 Jul;
11(7).
PMID: 37509605
A significant proportion of meningiomas are clinically aggressive, but there is currently no effective chemotherapy for meningiomas. An increasing number of studies have been conducted to develop targeted therapies, yet...
7.
Nakagawa-Saito Y, Mitobe Y, Suzuki S, Togashi K, Sugai A, Kitanaka C, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445993
The deregulation of the FOXM1 transcription factor is a key molecular alteration in ovarian cancer, contributing to the development and progression of ovarian cancer via activation of the target genes....
8.
Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Kitanaka C, et al.
Anticancer Res
. 2023 Feb;
43(3):1131-1138.
PMID: 36854532
Background/aim: Givinostat is a pan-histone deacetylase (HDAC) inhibitor that has demonstrated excellent tolerability as well as efficacy in patients with polycythemia vera. Accumulating in vitro and in vivo evidence suggests...
9.
Mitobe Y, Nakagawa-Saito Y, Togashi K, Suzuki S, Sugai A, Matsuda K, et al.
Anticancer Res
. 2022 Oct;
42(10):4727-4733.
PMID: 36192008
Background/aim: The development of pharmacological inhibitors targeting negative regulators of p53, such as murine double minute (MDM) 2 and, more recently, MDM4, has been actively pursued as a potential strategy...
10.
Ohno M, Kitanaka C, Miyakita Y, Tanaka S, Sonoda Y, Mishima K, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077758
Glioblastoma (GBM) inevitably recurs due to a resistance to current standard therapy. We showed that the antidiabetic drug metformin (MF) can induce the differentiation of stem-like glioma-initiating cells and suppress...